Literature DB >> 23155285

Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.

Yin Lin1, Wan-Yu Lin, Chia-Hung Kao, Kuo-Yang Yen, Shang-Wen Chen, Jun-Jun Yeh.   

Abstract

BACKGROUND: This study aimed to determine the relationship between the pre-operative metabolic tumor volume (MTV) and the disease-free survival (DFS) of patients with stage I non-small cell lung cancer (NSCLC) using F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography-computed tomography (PET-CT) scanning.
MATERIALS AND METHODS: Data from sixty patients with stage I NSCLC who had undergone preoperative F-18 FDG PET-CT scanning were retrospectively analyzed. The early and late maximum standardized uptake values (eSUVm and lSUVm, respectively) were measured from attenuation-corrected F-18 FDG PET-CT images. Three MTV segmentation methods were applied as an isocontour at an early SUV of 2.5 (MTV2.5) or using fixed thresholds of either 40% (MTV40%) or 50% (MTV50%) of the maximum intratumoral F-18 FDG activity. DFS was compared by employing the Kaplan-Meier method, using the median values as cutoffs for each parameter. The log-rank test and Cox regression were performed to explore the effect of the different MTV variables on DFS. Time-dependent receiver operating characteristic (ROC) curves were created to evaluate the predictive performance.
RESULTS: During a median follow-up duration of 24 months, two patients died of disease progression, and 11 experienced recurrent tumors (eight intrathoracic tumors, two distant metastasis, and one both types of recurrences). The univariate analyses showed that pathological stage 1B, histological type of squamous cell carcinoma, male sex, maximum tumor size over 2 cm, eSUVm, lSUVm, and MTV2.5 were associated with reduced DFS. Patients who had tumors with large eSUVm or large lSUVm had a significantly lower 2-year DFS, compared with patients who had smaller tumors (65% vs. 96%, p=0.002; 63% vs. 96%, p=0.000). Patients with an MTV2.5 greater than 9.8 ml had a lower 2-year DFS than those with an MTV of 9.8 ml or greater (59 vs. 85%, p=0.02). However, multivariate analysis showed that lSUVm over 3.4 was the only parameter that exhibited an impact on DFS (p=0.05, hazard ratio=10.7), and the observed influence was marginal.
CONCLUSION: For patients with stage I NSCLC treated with surgery, preoperative MTV parameters have a limited prognostic value for predicting DFS.

Entities:  

Mesh:

Year:  2012        PMID: 23155285

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  21 in total

1.  A Pilot Study of Texture Analysis of Primary Tumor [18F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Tetsuya Shinaji; Masaya Aoki; Atsushi Tani; Yoshiaki Nakabeppu; Masayuki Nakajo; Masami Sato; Takashi Yoshiura
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

2.  Prone position [18F]FDG PET/CT to reduce respiratory motion artefacts in the evaluation of lung nodules.

Authors:  Hyung Ju Lee; Hye Joo Son; Mijin Yun; Jung Won Moon; Yoo Na Kim; Ji Young Woo; Suk Hyun Lee
Journal:  Eur Radiol       Date:  2021-04-14       Impact factor: 5.315

3.  18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?

Authors:  A Tuba Kendi; Amanda Corey; Kelly R Magliocca; Dana C Nickleach; James Galt; Jeffrey M Switchenko; Mark W El-Deiry; J Trad Wadsworth; Patricia A Hudgins; Nabil F Saba; David M Schuster
Journal:  Eur J Radiol       Date:  2015-03-14       Impact factor: 3.528

4.  Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.

Authors:  Chenpeng Zhang; Chuanhong Liao; Bill C Penney; Daniel E Appelbaum; Cassie A Simon; Yonglin Pu
Journal:  Radiology       Date:  2015-01-14       Impact factor: 11.105

Review 5.  Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

Authors:  Hyung-Jun Im; Tyler Bradshaw; Meiyappan Solaiyappan; Steve Y Cho
Journal:  Nucl Med Mol Imaging       Date:  2017-09-19

Review 6.  Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.

Authors:  Muhammad Kashif Rahim; Sung Eun Kim; Hyeongryul So; Hyung Jun Kim; Gi Jeong Cheon; Eun Seong Lee; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-01-22

7.  FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.

Authors:  Zachary A Kohutek; Abraham J Wu; Zhigang Zhang; Amanda Foster; Shaun U Din; Ellen D Yorke; Robert Downey; Kenneth E Rosenzweig; Wolfgang A Weber; Andreas Rimner
Journal:  Lung Cancer       Date:  2015-05-28       Impact factor: 5.705

8.  Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?

Authors:  Ayse Tuba Karagulle Kendi; Kelly Magliocca; Amanda Corey; Dana C Nickleach; James Galt; Kristin Higgins; Jonathan J Beitler; Mark W El-Deiry; J Trad Wadsworth; Patricia A Hudgins; Nabil F Saba; David M Schuster
Journal:  Clin Nucl Med       Date:  2015-03       Impact factor: 7.794

9.  FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Authors:  Hyun Woo Chung; Kye Young Lee; Hee Joung Kim; Wan Seop Kim; Young So
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-06       Impact factor: 4.553

10.  Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.

Authors:  Hyung-Jun Im; Kyoungjune Pak; Gi Jeong Cheon; Keon Wook Kang; Seong-Jang Kim; In-Joo Kim; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.